Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

Sanofi India Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 1.56700
forwardPE 33.91522
debtToEquity 2.24300
earningsGrowth -0.33700
revenueGrowth -0.25800
grossMargins 0.51356
operatingMargins 0.21111
trailingEps 136.24000
forwardEps 203.77000

SANOFI's current ratio being 1.567 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, SANOFI can easily cover its immediate liabilities, reflecting solid financial health.
Sanofi India Limited's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that Sanofi India Limited might struggle to maintain its current profit levels.
Positive gross and operating margins for SANOFI suggest that the company is operating profitably. These margins highlight SANOFI's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
Sanofi India Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Sanofi India Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

Over time, SANOFI's price projections have been gradually lowered, signaling declining confidence in the company's future outlook. The downward revisions suggest analysts are becoming more cautious about SANOFI's potential for growth.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


Recent analysis shows a strong buy bias for Sanofi India Limited, encouraging investors to view it as a solid investment option. The positive sentiment surrounding Sanofi India Limited suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.